References
- Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respirat Med. 2017;5(9):691–706. doi:https://doi.org/10.1016/S2213-2600(17)30293-X.
- Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000;161(5):1720–1745. doi:https://doi.org/10.1164/ajrccm.161.5.9903102.
- McBrien CN, Menzies-Gow A. The Biology of Eosinophils and Their Role in Asthma. Front Med (Lausanne)). 2017;4:93. doi:https://doi.org/10.3389/fmed.2017.00093.
- Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol. 2007;119(6):1303–1310. doi:https://doi.org/10.1016/j.jaci.2007.03.048.
- Ohkawara Y, Yamauchi K, Maruyama N, et al. In situ expression of the cell adhesion molecules in bronchial tissues from asthmatics with air flow limitation: in vivo evidence of VCAM-1/VLA-4 interaction in selective eosinophil infiltration. Am J Respir Cell Mol Biol. 1995;12(1):4–12. doi:https://doi.org/10.1165/ajrcmb.12.1.7529029.
- Harkness LM, Ashton AW, Burgess JK. Asthma is not only an airway disease, but also a vascular disease. Pharmacol Ther. 2015;148:17–33. doi:https://doi.org/10.1016/j.pharmthera.2014.11.010.
- Zilberberg L, Shinkaruk S, Lequin O, et al. Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. J Biol Chem. 2003;278(37):35564–35573. doi:https://doi.org/10.1074/jbc.M304435200.
- Gonçalves M, Estieu-Gionnet K, Berthelot T, et al. Design, synthesis, and evaluation of original carriers for targeting vascular endothelial growth factor receptor interactions. Pharm Res. 2005;22(8):1411–1421. doi:https://doi.org/10.1007/s11095-005-5265-9.
- Bakakos P, Patentalakis G, Papi A. Vascular biomarkers in asthma and COPD. Curr Top Med Chem. 2016;16(14):1599–1609. doi:https://doi.org/10.2174/1568026616666150930121157.
- Lee YC, Lee HK. Vascular endothelial growth factor in patients with acute asthma. J Allergy Clin Immunol. 2001;107(6):1106–1106. doi:https://doi.org/10.1067/mai.2001.115628.
- Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol. 2001;107(2):295–301. doi:https://doi.org/10.1067/mai.2001.111928.
- Kazi AS, Lotfi S, Goncharova EA, et al. Vascular endothelial growth factor-induced secretion of fibronectin is ERK dependent. Am J Physiol Lung Cell Mol Physiol. 2004;286(3):L539–545. doi:https://doi.org/10.1152/ajplung.00130.2003.
- Lee HY, Hur J, Kim IK, et al. Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model. Exp Lung Res. 2017;43:1–10. doi:https://doi.org/10.1080/01902148.2017.1339141.
- Yuksel H, Yilmaz O, Karaman M, et al. Role of vascular endothelial growth factor antagonism on airway remodeling in asthma. Ann Allergy Asthma Immunol. 2013;110(3):150–155. doi:https://doi.org/10.1016/j.anai.2012.12.015.
- Bikfalvi A. Recent developments in the inhibition of angiogenesis: examples from studies on platelet factor-4 and the VEGF/VEGFR system. Biochem Pharmacol. 2004;68(6):1017–1021. doi:https://doi.org/10.1016/j.bcp.2004.05.030.
- Myou S, Leff AR, Myo S, et al. Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT. J Exp Med. 2003;198(10):1573–1582. doi:https://doi.org/10.1084/jem.20030298.
- Padrid P, Snook S, Finucane T, et al. Persistent airway hyperresponsiveness and histologic alterations after chronic antigen challenge in cats. Am J Respir Crit Care Med. 1995;151(1):184–193. doi:https://doi.org/10.1164/ajrccm.151.1.7812551.
- (GINA) GIfA. Difficult-to-treat & severe asthma in adolescent and adult patients. Diagnosis and management (updated April 2019). 2019.
- Bakakos A, Loukides S, Bakakos P. Severe eosinophilic asthma. J Clin Med. 2019;8:1375. doi:https://doi.org/10.3390/jcm8091375.
- Mitzner W, Wagner EM. Vascular remodeling in the circulations of the lung. J Appl Physiol (1985)). 2004;97(5):1999–2004. doi:https://doi.org/10.1152/japplphysiol.00473.2004.
- Elices MJ, Leukocyte integrins. In: Cheresh DA, Mecham RP. eds. Integrins. San Diego: Academic Press; 1994:163–194.
- Lee SY, Kim JS, Lee JM, et al. Inhaled corticosteroid prevents the thickening of airway smooth muscle in murine model of chronic asthma. Pulm Pharmacol Ther. 2008;21(1):14–19. doi:https://doi.org/10.1016/j.pupt.2006.10.009.
- Mithieux SM, Weiss AS. Elastin. Adv Protein Chem. 2005;70:437–461. doi:https://doi.org/10.1016/s0065-3233(05)70013-9.
- Reddel CJ, Weiss AS, Burgess JK. Elastin in asthma. Pulm Pharmacol Ther. 2012;25(2):144–153. doi:https://doi.org/10.1016/j.pupt.2012.02.001.
- Mostaço-Guidolin LB, Osei ET, Ullah J, et al. Defective fibrillar collagen organization by fibroblasts contributes to airway remodeling in asthma. Am J Respir Crit Care Med. 2019;200(4):431–443. doi:https://doi.org/10.1164/rccm.201810-1855OC.
- Ito JT, Lourenço JD, Righetti RF, Tibério I, Prado CM, Lopes F. Extracellular matrix component remodeling in respiratory diseases: what has been found in clinical and experimental studies? Cells. 2019;8(4):342. doi:https://doi.org/10.3390/cells8040..
- Barron L, Gharib SA, Duffield JS. Lung pericytes and resident fibroblasts: busy multitaskers. Am J Pathol. 2016;186(10):2519–2531. doi:https://doi.org/10.1016/j.ajpath.2016.07.004.
- Michalik M, Wójcik-Pszczoła K, Paw M, et al. Fibroblast-to-myofibroblast transition in bronchial asthma. Cell Mol Life Sci. 2018;75(21):3943–3961. doi:https://doi.org/10.1007/s00018-018-2899-4.
- Jose PJ, Griffiths-Johnson DA, Collins PD, et al. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med. 1994;179(3):881–887. doi:https://doi.org/10.1084/jem.179.3.881.
- Pease JE, Williams TJ. Eotaxin and asthma. Curr Opin Pharmacol. 2001;1(3):248–253. doi:https://doi.org/10.1016/S1471-4892(01)00044-3.
- Pazdrak K, Justement L, Alam R. Mechanism of inhibition of eosinophil activation by transforming growth factor-beta. Inhibition of Lyn, MAP, Jak2 kinases and STAT1 nuclear factor. J Immunol. 1995;155(9):4454–4458.